Key facts
- Mile High Labs’s last known valuation is $128.0M (Aug 2020).
- It has raised $172.7M; the latest was Secondary Transaction - Private ($25.5M) in Mar 2026.
- Notable investors include Global Alternative Investment Management, Highlands Venture Partners, John DeJoria, Manta Capital Advisors.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mile High Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Mile High Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mile High Labs
Provider of cannabidiol (CBD) and cannabigerol (CBG) ingredients intended to launch and expand new products. The company offers a wide range of quality, compliant and scalable ingredients assembled through extraction, refining and co-packing services, enabling cannabinoid cultivators, manufacturers, retailers, and the marijuana industry to meet considerable demand.
- Sector
- Business Products and Services (B2B)
- HQ
- Broomfield, CO, United States
- Founded
- 2016
- Employees
- 53
- Website
- milehighlabs.com/
- Ownership
- Privately Held (backing)
Mile High Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mile High Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mile High Labs in its N-PORT filings yet. We sweep new filings monthly.